Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Diabetes: Update Bulletin [November 2014]

Product Code:
596200330
Release Date:
November 2014
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in Diabetes: Bydureon Pen; phase III data of Intarcia’s ITCA 650, AdCom, Saxenda (liraglutide 3mg), phase III results for omarigliptin and trelagliptin succinate, FDA approval of Invokamet, Tresiba BEGIN-YOUNG 1 phase III trial results and phase IIIb Ryzodeg data.

Highlights from this event update bulletin

  • How is the new Bydureon Pen formulation viewed?
  • Will ITCA 650, an ultra-long acting mini-osmotic pump formulation of exenatide, be able to compete in the GLP-1 analogue market?
  • How will Saxenda (liraglutide 3 mg) be prescribed?
  • What factors may limit the uptake of Saxenda?
  • How are the once-weekly DPP-IV inhibitors, omarigliptin and trelagliptin succinate, viewed?
  • Will the US launch of Invokamet (canagliflozin/metformin) impact the diabetes market?
  • Will results from BEGIN YOUNG 1 influence the way Tresiba is prescribed?
  • How do KOLs view the latest phase IIIb trials of Ryzodeg?

When you purchase the full report, you get access to this Update Bulletin.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved